Specialists Harness Genome Editing Technology for Blood Cell Biology Research.
In a groundbreaking study published in Cell, experts have employed an exceptionally precise genome-editing technology known as base editing to perform numerous targeted modifications on blood stem cells derived from patients’ bone marrow.
Gateway to Different Venues to Deepen Knowledge
This pioneering work marks the first instance of high-throughput base editing, a technique capable of making multiple single-base changes in DNA across multiple cells simultaneously, being applied to blood stem cells. The research team demonstrated how these precise alterations at the nucleotide level within genes can impact the biology of blood cells and offer potential treatments for conditions such as sickle cell anemia and leukemia. These findings open up avenues for researchers to deepen their understanding of the role gene variants play in various diseases affecting different cell types.
A New Approach to Find Breakthrough
Vijay Sankaran, a senior author of the study and an associate member at the Broad Institute of MIT and Harvard, expressed, “Our approach not only helps us determine whether a specific gene is implicated in a human disease but also sheds light on the precise molecular mechanisms underlying individual changes to that gene. This breakthrough provides us with a new roadmap for comprehending disease onset and devising effective treatments.”
Sankaran, who holds the Lodish Family Seat at Boston Children’s Hospital, serves as the Jan Ellen Heaven, MD Professor of Pediatrics at Harvard Medical School, and is a New York Stem Cell Robertson Investigator. He spearheaded this collaborative effort alongside Ramnik Xavier, a distinguished member of the Broad Institute and other associates. The study’s first author, Jorge Diego Martin-Rufino, is a Ph.D. candidate in Sankaran’s laboratory.
Collaboration of Success
“Conducting experiments based on disease-causing processes is essential for impacting patients suffering from blood disorders,” stated Xavier, who is also the Kurt J. Isselbacher Professor of Medicine at Harvard Medical School, the director of the Center for Computational and Integrative Biology, and a core member in the Department of Molecular Biology at Massachusetts General Hospital. “This remarkable collaboration among bench scientists, biotechnologists, and physicians has paved the way for identifying disease-associated variants in relevant cell types associated with blood disorders.”
By leveraging the power of base editing and gene regulation, this study represents a significant step forward in blood cell biology research. The utilization of CRISPR gene-editing technology has opened up new possibilities for genome editing, enabling scientists to explore the intricacies of gene function and its impact on various diseases. The results of this study not only advance our knowledge of blood cell biology but also provide crucial insights for the development of targeted therapies and precision medicine approaches.